Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects

Empagliflozin Ameliorates Ouabain-Induced Na+ and Ca2+ Dysregulations in Ventricular Myocytes in an Na+-Dependent Manner

(2022) Xiaodong Peng et al.   CARDIOVASCULAR DRUGS AND THERAPY

New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans

(2021) Laura Ferté et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

(2021) Thomas M. Maddox et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

(2021) B. Gaborit et al.   Cardiovascular Diabetology

Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycaemia: reduced repolarization reserve, neurohormonal stimulation, and heart failure exacerbate susceptibility

(2021) Bence Hegyi et al.   CARDIOVASCULAR RESEARCH

Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure

(2021) Xuan Li et al.   Journal of the American Heart Association

Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins

(2021) Sin-Hee Park et al.   Cardiovascular Diabetology

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

(2021) Hang-Long Li et al.   Cardiovascular Diabetology

Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions

(2021) Coert J Zuurbier et al.   CARDIOVASCULAR RESEARCH

The Cardiac Late Sodium Channel Current is a Molecular Target for the Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin

(2021) Koenraad Philippaert et al.   CIRCULATION

AMP-activated protein kinase: A remarkable contributor to preserve a healthy heart against ROS injury

(2021) Alice Marino et al.   FREE RADICAL BIOLOGY AND MEDICINE

Does the cardioprotective effect of Empagliflozin involve inhibition of the sodium-proton exchanger?

(2021) Elizabeth Murphy et al.   CARDIOVASCULAR RESEARCH

SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens

(2021) Yu Jin Chung et al.   CARDIOVASCULAR RESEARCH

Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure

(2021) Peter E Light   EUROPEAN HEART JOURNAL

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

(2021) James P Curtain et al.   EUROPEAN HEART JOURNAL

Effects of canagliflozin on human myocardial redox signalling: clinical implications

(2021) Hidekazu Kondo et al.   EUROPEAN HEART JOURNAL

Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species

(2021) Xiaoling Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

(2021) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells

(2021) Laween Uthman et al.   BIOMEDICINE & PHARMACOTHERAPY

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

(2021) Javed Butler et al.   CIRCULATION

Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction

(2021) Matthew K. Burrage et al.   CIRCULATION

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

(2021) Sharmaine Thirunavukarasu et al.   DIABETES

Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta‐analyses

(2021) Chu Lin et al.   DIABETES OBESITY & METABOLISM

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

(2021) Javed Butler et al.   EUROPEAN HEART JOURNAL

Ketone Ester D‐β‐Hydroxybutyrate‐(R)‐1,3 Butanediol Prevents Decline in Cardiac Function in Type 2 Diabetic Mice

(2021) Phung N. Thai et al.   Journal of the American Heart Association

Chronic exogenous ketone supplementation blunts the decline of cardiac function in the failing heart

(2021) Shingo Takahara et al.   ESC Heart Failure

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure

(2020) Nikole J. Byrne et al.   Circulation-Heart Failure

Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress

(2020) Panagiota Efstathia Nikolaou et al.   ANTIOXIDANTS & REDOX SIGNALING

Abnormalities in Sodium Current and Calcium Homeostasis as Drivers of Arrhythmogenesis in Hypertrophic Cardiomyopathy

(2020) Raffaele Coppini et al.   CARDIOVASCULAR RESEARCH

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation

(2020) Detmar Kolijn et al.   CARDIOVASCULAR RESEARCH

Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance

(2020) Milton Packer   CIRCULATION

Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice

(2020) Xiaodong Sun et al.   DIABETES

Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

(2020) Byambasuren Ganbaatar et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

(2020) Mark C. Petrie et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Myocardial Ketones Metabolism in Heart Failure

(2020) Qutuba G. Karwi et al.   JOURNAL OF CARDIAC FAILURE

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

(2020) So Ra Kim et al.   Nature Communications

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats

(2020) Atsushi Kuno et al.   Scientific Reports

Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator

(2020) Detmar Kolijn et al.   Frontiers in Physiology

Cardiac ketone body metabolism

(2020) Azrul Abdul Kadir et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Chronically Elevating Circulating Ketones Can Reduce Cardiac Inflammation and Blunt the Development of Heart Failure

(2020) Nikole J. Byrne et al.   Circulation-Heart Failure

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

(2020) Alexander J M Brown et al.   EUROPEAN HEART JOURNAL

Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology

(2020) Petar M. Seferović et al.   EUROPEAN JOURNAL OF HEART FAILURE

Late sodium current in atrial cardiomyocytes contributes to the induced and spontaneous atrial fibrillation in rabbit hearts

(2020) Yanpeng Chu et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Ketone Body, 3-Hydroxybutyrate: Minor Metabolite - Major Medical Manifestations

(2020) Niels Møller   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Na+ controls hypoxic signalling by the mitochondrial respiratory chain

(2020) Pablo Hernansanz-Agustín et al.   NATURE

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

(2020) Donato Cappetta et al.   PHARMACOLOGICAL RESEARCH

Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells

(2020) Laween Uthman et al.   CARDIOVASCULAR DRUGS AND THERAPY

Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes

(2020) Steffen Pabel et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intracellular sodium elevation reprograms cardiac metabolism

(2020) Dunja Aksentijević et al.   Nature Communications

Empagliflozin inhibits Na + /H + exchanger activity in human atrial cardiomyocytes

(2020) Maximilian Trum et al.   ESC Heart Failure

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

(2020) Stefan D. Anker et al.   CIRCULATION

Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF

(2020) Yan Deng et al.   CIRCULATION RESEARCH

Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure

(2020) Salva R. Yurista et al.   Circulation-Heart Failure

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

(2020) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction

(2020) Rio P. Juni et al.   KIDNEY INTERNATIONAL

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

(2020) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts

(2020) Hong Zhang et al.   Frontiers in Cardiovascular Medicine

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus

(2020) Chi Young Shim et al.   CIRCULATION

Delayed ischemic contracture onset by Empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts

(2019) Laween Uthman et al.   CARDIOVASCULAR RESEARCH

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

(2019) David Fitchett et al.   CIRCULATION

Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients

(2019) Roni Nielsen et al.   CIRCULATION

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

(2019) Eri T. Kato et al.   CIRCULATION

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

(2019) Chenguang Li et al.   Cardiovascular Diabetology

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research

(2019) Amber L. Beitelshees et al.   DIABETES

Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction

(2019) Salva R. Yurista et al.   EUROPEAN JOURNAL OF HEART FAILURE

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats

(2019) Ting-I Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Angiotensin II‐induced redox‐sensitive SGLT1 and 2 expression promotes high glucose‐induced endothelial cell senescence

(2019) Sonia Khemais‐Benkhiat et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

(2019) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice

(2019) Mei Xue et al.   CLINICAL SCIENCE

SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice

(2019) Rebeca Ortega et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac myofibroblasts: Novel translational clues to EMPA-REG OUTCOME

(2019) Sean Kang et al.   CANADIAN JOURNAL OF CARDIOLOGY

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial

(2019) Subodh Verma et al.   CIRCULATION

Increase of late sodium current contributes to enhanced susceptibility to atrial fibrillation in diabetic mice

(2019) Xuexin Jin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model

(2019) Mark T. Waddingham et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway

(2019) Qingguo Lu et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Heart Failure with Preserved Ejection Fraction

(2018) James D. Gladden et al.   Annual Review of Medicine

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

(2018) Daisuke Matsutani et al.   Cardiovascular Diabetology

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

(2018) Karin Rådholm et al.   CIRCULATION

Calcium Signaling and Reactive Oxygen Species in Mitochondria

(2018) Edoardo Bertero et al.   CIRCULATION RESEARCH

Treatment with D-β-hydroxybutyrate protects heart from ischemia/reperfusion injury in mice

(2018) Yongsheng Yu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

SGLT2 inhibition and heart failure—current concepts

(2018) Joaquim Silva Custodio et al.   HEART FAILURE REVIEWS

Enhanced late sodium current underlies pro-arrhythmic intracellular sodium and calcium dysregulation in murine sodium channelopathy

(2018) Mathilde R. Rivaud et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

(2018) Sarah J. Mancini et al.   Scientific Reports

Glucose-Lowering Therapies in Patients With Concomitant Diabetes Mellitus and Heart Failure

(2018) Javed Butler et al.   JACC-Heart Failure

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

(2018) Hao Zhou et al.   Redox Biology

Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study

(2018) Desiree Abdurrachim et al.   DIABETES OBESITY & METABOLISM

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF

(2018) Sanjiv J Shah et al.   EUROPEAN HEART JOURNAL

Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes

(2018) Thomas A. Zelniker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Innate immunity as a target for acute cardioprotection

(2018) Coert J Zuurbier et al.   CARDIOVASCULAR RESEARCH

Empagliflozin directly improves diastolic function in human heart failure

(2018) Steffen Pabel et al.   EUROPEAN JOURNAL OF HEART FAILURE

Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.

(2018) Hiroto Oshima et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients

(2018) Laween Uthman et al.   Frontiers in Physiology

Forty Years of Sodium Channels: Structure, Function, Pharmacology, and Epilepsy

(2017) William A. Catterall   NEUROCHEMICAL RESEARCH

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

(2017) Sebastian Steven et al.   Redox Biology

Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart

(2017) Anne Van Steenbergen et al.   Scientific Reports

β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes

(2016) Manabu Nagao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Empagliflozin’s Fuel Hypothesis: Not so Soon

(2016) Gary D. Lopaschuk et al.   Cell Metabolism

The Failing Heart Relies on Ketone Bodies as a Fuel

(2016) Gregory Aubert et al.   CIRCULATION

Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes

(2016) Ele Ferrannini et al.   DIABETES

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

(2016) Subodh Verma et al.   DIABETES CARE

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

(2016) Ralph A. DeFronzo et al.   Nature Reviews Nephrology

Late sodium current: A mechanism for angina, heart failure, and arrhythmia

(2016) Jonathan C. Makielski   TRENDS IN CARDIOVASCULAR MEDICINE

β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation

(2016) Ha Ram Bae et al.   Oncotarget

Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction

(2016) Constantijn Franssen et al.   JACC-Heart Failure

Role of Sodium and Calcium Dysregulation in Tachyarrhythmias in Sudden Cardiac Death

(2015) S. Wagner et al.   CIRCULATION RESEARCH

Cardiac late Na+ current: Proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress

(2015) Luiz Belardinelli et al.   HEART RHYTHM

The Importance of NLRP3 Inflammasome in Heart Failure

(2015) Brittany Butts et al.   JOURNAL OF CARDIAC FAILURE

Na+channel function, regulation, structure, trafficking and sequestration

(2015) Ye Chen-Izu et al.   JOURNAL OF PHYSIOLOGY-LONDON

The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease

(2015) Yun-Hee Youm et al.   NATURE MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

ADP-stimulated contraction: A predictor of thin-filament activation in cardiac disease

(2015) Vasco Sequeira et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Calcium and ROS: A mutual interplay

(2015) Agnes Görlach et al.   Redox Biology

Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure

(2015) Istvan Baczko et al.   CURRENT PHARMACEUTICAL DESIGN

Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4

(2014) N. Hamdani et al.   CARDIOVASCULAR RESEARCH

Gigantic Business

(2014) Wolfgang A. Linke et al.   CIRCULATION RESEARCH

Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?

(2014) G. Frommeyer et al.   CURRENT MEDICINAL CHEMISTRY

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

(2014) Atsuo Tahara et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Electrophysiological changes in heart failure and their implications for arrhythmogenesis

(2013) R. Coronel et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model

(2013) Nazha Hamdani et al.   Circulation-Heart Failure

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes

(2013) Can M. Sag et al.   FREE RADICAL BIOLOGY AND MEDICINE

Cardiac sodium channelopathy associated withSCN5Amutations: electrophysiological, molecular and genetic aspects

(2013) Carol Ann Remme   JOURNAL OF PHYSIOLOGY-LONDON

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction

(2013) Walter J. Paulus et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ketone bodies as signaling metabolites

(2013) John C. Newman et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction

(2012) Nazha Hamdani et al.   CARDIOVASCULAR RESEARCH

Suppression of Oxidative Stress by  -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor

(2012) T. Shimazu et al.   SCIENCE

Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo

(2011) Kalkidan Bishu et al.   CIRCULATION

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Calcium-regulated transcriptional pathways in the normal and pathologic heart

(2011) Angel Zarain-Herzberg et al.   IUBMB LIFE

Exercise Training Improves Exercise Capacity and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction

(2011) Frank Edelmann et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Vascular Inflammation in Obesity and Sleep Apnea

(2010) Sanja Jelic et al.   CIRCULATION

Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction

(2010) Dirk Westermann et al.   Circulation-Heart Failure

Inflammatory Biomarkers in Heart Failure Revisited: Much More than Innocent Bystanders

(2009) Stephan von Haehling et al.   Heart Failure Clinics

Chronic inhibition of the Na+/H+- exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling

(2008) A Baartscheer et al.   BRITISH JOURNAL OF PHARMACOLOGY